Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Elderly EGFR Wild-type Lung Adenocarcinoma
NCT03728374Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in lung adenocarcinoma, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03728374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728374.